Investigators at Division of Macromolecular Prodrugs Discuss Findings in Nanoparticles (Engineered drug-protein nanoparticle complexes for folate receptor targeting)
By a News Reporter-Staff News Editor at Journal of Engineering -- New research on Nanoparticles is the subject of a report. According to news reporting originating from Freiburg, Germany, by VerticalNews correspondents, research stated, "Nanomaterials that are used in therapeutic applications need a high degree of uniformity and functionality which can be difficult to attain. One strategy for fabrication is to utilize the biological precision afforded by recombinant synthesis."
Our news editors obtained a quote from the research from the Division of Macromolecular Prodrugs, "Through protein engineering, we have produced similar to 27-nm dodecahedral protein nanoparticles using the thermostable E2 subunit of pyruvate dehydrogenase as a scaffold and added optical imaging, drug delivery, and tumor targeting capabilities. Cysteines in the internal cavity of the engineered caged protein scaffold (E2 variant D381C) were conjugated with maleimide-bearing Alexa Fluor 532 (AF532) and doxorubicin (DOX). The external surface was functionalized with polyethylene glycol (PEG) alone or with the tumor-targeting ligand folic acid (FA) through a PEG linker. The resulting bi-functional nanoparticles remained intact and correctly assembled. The uptake of FA-displaying nanoparticles (D381C-AF532-PEG-FA) by cells overexpressing the folate receptor was approximately six times greater than of non-targeting nanoparticles (D381C-AF532-PEG) and was confirmed to be FA-specific. Nanoparticles containing DOX were all cytotoxic in the low micromolar range."
According to the news editors, the research concluded: "To our knowledge, this work is the first time that acid-labile drug release and folate receptor targeting have been simultaneously integrated onto recombinant protein nanoparticles, and it demonstrates the potential of using biofabrication strategies to generate functional nanomaterials."
For more information on this research see: Engineered drug-protein nanoparticle complexes for folate receptor targeting. Biochemical Engineering Journal, 2014;89():33-41. Biochemical Engineering Journal can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Biochemical Engineering Journal - www.elsevier.com/wps/product/cws_home/600804)
The news editors report that additional information may be obtained by contacting D.M. Ren, Tumor Biol Center, Div Macromol Prodrugs, D-79106 Freiburg, Germany. Additional authors for this research include F. Kratz and S.W. Wang.
Keywords for this news article include: Freiburg, Germany, Europe, Emerging Technologies, Engineering, Nanomaterial, Nanotechnology, Protein Nanoparticles
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC